Significant agreements (Tables)

9 Months Ended

Sep. 30, 2019

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Summary of revenue recognized from collaboration arrangements

The following table summarizes the revenue recognized in the Company’s condensed consolidated statements of operations and comprehensive loss from the Company’s collaboration agreements (in thousands):

	Three Months				Nine Months
	Ended				Ended
	September 30,				September 30,
	2019		2018		2019		2018
Collaboration revenues
AstraZeneca	$	441	$	388	$	1,229	$	1,078
Sanofi		—		1,047		6,016		3,258
Oxurion		—		175		—		1,743
Dementia Discovery Fund		173		—		275		—
Material transfer agreement		—		—		1,000		—
Total collaboration revenues	$	614	$	1,610	$	8,520	$	6,079

Summary of changes in the balances of the Company’s contract assets and liabilities

The following table presents changes in the balances of the Company’s contract assets and liabilities (in thousands):

	Balance at						Impact of		Balance at
	Beginning of						Exchange		End of
	Year		Additions		Deductions		Rates		Period
Period ended December 31, 2018
Contract assets	$	—	$	91	$	(91)	$	—	$	—
Contract liabilities:
Deferred revenue
AstraZeneca collaboration deferred revenue		—		5,350		(466)		(157)		4,727
Sanofi collaboration deferred revenue		14,467		—		(4,006)		(553)		9,908
Total deferred revenue	$	14,467	$	5,350	$	(4,472)	$	(710)	$	14,635

	Balance at						Impact of		Balance at
	Beginning of						Exchange		End of
	Period		Additions		Deductions		Rates		Period
Period ended September 30, 2019
Contract assets	$	—	$	149	$	(103)	$	—	$	46
Contract liabilities:
Deferred revenue
AstraZeneca collaboration deferred revenue		4,727		24		(35)		(167)		4,549
Sanofi collaboration deferred revenue		9,908		—		(5,286)		(116)		4,506
DDF collaboration deferred revenue		—		1,114		(275)		(31)		808
Total deferred revenue	$	14,635	$	1,138	$	(5,596)	$	(314)	$	9,863

Summary of recognition of revenues as a result of changes in contract asset and contract liability balances

During the three and nine months ended September 30, 2019 and 2018, the Company recognized the following revenues as a result of changes in the contract asset and the contract liability balances in the respective periods (in thousands):

	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2019		2018		2019		2018
Revenue recognized in the period from:
Revenue recognized based on proportional performance	$	(173)	$	(1,121)	$	(310)	$	(3,408)
Revenue recognized based on expiration of material rights		—		—		(5,286)		—
Total	$	(173)	$	(1,121)	$	(5,596)	$	(3,408)

AstraZeneca

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Summary of allocation of transaction price to separate performance obligations

Based on the relative standalone selling price, the allocation of the transaction price to the separate performance obligations at the inception of the arrangement is as follows (in thousands):

	Allocation of
Performance Obligations	Transaction Price
Target Three Research License and Related Services	$	650
Target 3 Material Right		1,504
Target 4 Material Right		1,204
Target 5 Material Right		1,165
Target 6 Material Right		1,127
	$	5,650

Sanofi

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Summary of allocation of transaction price to separate performance obligations

Based on the relative standalone selling price, the allocation of the transaction price to the separate performance obligations at the inception of the arrangement is as follows (in thousands):

	Allocation of
Performance Obligations	Transaction Price
Sickle Cell Research License and Related Services	$	1,405
Hemophilia Research License and Related Services		2,811
Sickle Cell License Option Material Right		5,286
Hemophilia License Option Material Right		4,698
	$	14,200